This inventor holds 1 USPTO granted patent and 4 published patent applications. Top assignee: Juno Therapeutics Gmbh. Active years: 2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2025
Title: **Madeline Williams: Innovating in Immunotherapy**
Introduction
Madeline Williams is an accomplished inventor based in Seattle, WA, known for her significant contributions to the field of immunotherapy. With a keen focus on receptor tyrosine kinase-like orphan receptor 1 (ROR1), her inventive work has the potential to transform therapeutic approaches in treating various diseases.
Latest Patents
Madeline holds one patent titled "Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ROR1)." This patent encompasses ROR1-binding molecules, specifically human antibodies and their fragments designed to target ROR1. It outlines the development of recombinant receptors, including chimeric antigen receptors (CARs) that utilize these antibodies and fragments. The patent further details polynucleotides encoding such antibodies, as well as genetically engineered cells incorporating these ROR1-binding proteins and receptors. This innovation is pivotal for advancing methods in adoptive cell therapy.
Career Highlights
In her professional journey, Madeline is currently employed at Juno Therapeutics GmbH, a biotechnology company renowned for its groundbreaking work in cellular therapies. Her expertise in producing ROR1-specific antibodies illustrates her commitment to developing innovative solutions in cancer treatment and beyond.
Collaborations
Madeline collaborates with talented colleagues including Andreia Costa and Rupesh Amin. Their teamwork exemplifies the spirit of collaboration in scientific research, leading to significant innovations in the biotechnology sector.
Conclusion
Madeline Williams stands out as a remarkable inventor whose work in immunotherapy represents the confluence of science and innovation. Her patent on ROR1-targeting therapeutics not only demonstrates her ingenuity but also promises to enhance the efficacy of cancer treatments. As she continues her work at Juno Therapeutics GmbH, the potential impact of her contributions is boundless, inspiring a new era in medical science.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile